BioCentury
ARTICLE | Clinical News

Autologous T cell therapy against CD19 regulatory update

August 22, 2016 7:00 AM UTC

EMA granted PRIority MEdicines (PRIME) designation to KTE-C19 from Kite to treat refractory diffuse large B cell lymphoma (DLBCL). KTE-C19 comprises autologous T cells genetically modified to express ...